Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study.

ABSTRACT:

SUBMITTER: Assanto GM 

PROVIDER: S-EPMC10631717 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature